Neutral Backbone Modifications Enhance the Pharmacokinetics and Biodistribution of Antibody–Oligonucleotide Conjugates with High Drug-to-Antibody Ratios
Antibody–oligonucleotide conjugates (AOCs) enable targeted delivery of small interfering RNAs (siRNAs) by coupling them to antibodies for receptor-mediated uptake, enhancing tissue specificity and therapeutic potential. A key determinant of AOC performance is the drug-to-antibody ratio (DAR), which influences pharmacok...